Paid Clinical Trials in Atlanta

Dr. Ahmed Zayed

Written by Dr. Ahmed Zayed

Board-certified Physician | Graduate w/ Honors Faculty of Medicine | Alexandria, Egypt

Situated in Georgia, the city of Atlanta stands as an epicenter for advancements in healthcare and clinical research. 

Clinical Research in Atlanta

Welcome to Atlanta, where experts explore new frontiers and push the boundaries in medicine. Clinical research Atlanta, Georgia is the engine that drives future healthcare solutions forward. Our platform is here to help you make a change.

We can connect you to clinical research centers in Atlanta that have active or future trials. Your contribution can shape the medicine of tomorrow. 

Clinical Trials For Disease Areas in Atlanta 

Atlanta clinical research centers focus on medical and treatment advances within many fields of medicine. They conduct a multitude of trials in various therapeutic areas. Every research facility has a strong reputation for quality practices and a solid track record.

Some of the most popular areas of research are COVID-19 booster trials, diabetes and weight loss studies, Lyme disease treatments, and cancer research. 

For example, the Atlanta Center for Clinical Research (ACCR) is a renowned clinical research facility that does Phase II, III, and IV clinical trials. They’ve performed about 130 studies with 1,700 patients signing up. 

As new treatments and medical devices enter the market, clinical trials have increased by 25% in the last 4 years. However, there is still a gap between the number of trials offered and the number of participants necessary to carry out these studies.

We can’t have therapeutics if we don’t have research studies. You can make a difference. The moment you join an Atlanta study, you become a part of medical innovation. Apply now!

Follow-up Visit of High Risk Infants
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Consent for Use of Stored Patient Specimens for Future Testing
Recruiting
The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other tissues) for future studies that may include genetic testing.
Gender:
ALL
Ages:
All
Trial Updated:
09/20/2024
Locations: Univ of Southern California / LA County USC Med Ctr, Los Angeles, California
Conditions: HIV Infections
Generic Database of Very Low Birth Weight Infants
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Pompe Pregnancy Sub-Registry
Recruiting
This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglucosidase alfa or avalglucosidase alfa) and irrespective of the commercial product with which she may be treated. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standa... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
11/19/2024
Locations: Barrow Neurol Group- Site Number : 840087, Phoenix, Arizona
Conditions: Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
Recruiting
This study will evaluate the effectiveness of culturally competent psychoeducational empowerment sessions in treating suicidal African-American women who are in abusive relationships.
Gender:
FEMALE
Ages:
Between 18 years and 64 years
Trial Updated:
11/08/2024
Locations: Grady Hospital, Atlanta, Georgia
Conditions: Battered Women, Suicide, Attempted
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: Pillar Clinical Research, Bentonville, Arkansas +1 locations
Conditions: Schizophrenia
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Tucson, Arizona +1 locations
Conditions: Ulcerative Colitis
CERENOVUS Neurothrombectomy Devices Registry
Recruiting
A post-market registry evaluating the EmboTrap® Revascularization Device and CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2022
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cerebral Stroke
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Goodyear, Arizona
Conditions: Neoplasms
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +1 locations
Conditions: Multiple Myeloma

Time is money. And you should be paid for your services. Through paid research studies in Atlanta, you are getting financial compensation. You can earn from $50 to $300 per day/visit. 

Top-tier public research centers, like Georgia State University, may provide higher forms of compensation. Especially if a trial has a higher risk and it is in its early phase. While smaller trial sites and private sector policies could come with lower monetary gain. 

Other than cash payments, you can receive reimbursements for travel expenses, meals, and accommodations related to the trial. This is why many students apply for a trial.

Clinical Trials For Health Volunteers in Atlanta 

Clinical research organizations in Atlanta are currently seeking health volunteers to take part in trials. Health volunteers are the lifeblood of medical research.

As a health volunteer, your involvement can have far-reaching effects. The data and information you provide can prove invaluable to researchers and allow them to make informed decisions that can benefit society as a whole. 

You bring unique perspectives, experiences, and insights that are essential for the success of research studies. In other words, you help set the stage for the next wave of medical breakthroughs and innovations.

Interested in applying for a clinical trial? Check out the list below. Here, you can find all the active and future trials in Atlanta, Georgia. 

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Recruiting
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Anemia, Sickle Cell, Healthy Volunteers
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Par... Read More
Gender:
ALL
Ages:
Between 45 years and 85 years
Trial Updated:
06/24/2025
Locations: Collaborative Neuroscience Network - CNS, Los Alamitos, California
Conditions: Alzheimer Disease, Healthy

Medical Discoveries and Innovation in Atlanta

Atlanta boasts a growing health ecosystem and medical technology. The city is a national leader in vaccine research, clinical trials, information technology, and medical device development. 

The Emory Vaccine Center (EVC) has made fundamental advances in virology, immunology, and vaccine research. Experts work with faculty members, students, and staff to launch and explore different ideas about new projects, medications, and processes. 

But, top-tier universities are not the only ones who’ve benefited the medical community. Atlanta startups have also left a mark on the healthcare industry. Endoluxe, a medical device startup raised $1 million for expansion. This company has made it easier to examine the esophagus with video processors and wireless cameras.

Why Atlanta Is A Great Place For Clinical Research 

About 20% of medical therapies and cures have different effects on various ethnicities. 

In the last few years, the lack of diversity in clinical trials has become a real problem. There is a significant lack of representation of people of color (POC) in clinical trials, such as trials for diabetes or cancer.

According to the latest FDA report, only 7% of clinical trial participants were identified as Black and merely 13% were Hispanic. 

In Atlanta, Georgia, the population is very diverse. About 49.3% of its residents are Black, 38% are White, 4.74% are Asian, 2.43% are Multiracial, and 2.42% are White Hispanic. This diversity is crucial for ensuring that medical interventions are effective across different demographics.

The city also has a well-established network of clinical research professionals, making it an attractive destination for both sponsors and participants.